Great opportunities for developers of biosimilars
Between 2009 and 2019 blockbuster biopharmaceuticals with a total value of over 50 billion $US will lose patent protection.
05-Dec-2008 -
Biopharmaceuticals or biologicals are drugs synthesized by “recombinant DNA technology”, a gene technological process developed in the mid seventies. In contrast to classic low-molecular drugs like Aspirin®, for example, which can be produced by way of chemical synthesis due to their simple ...
Amgen
biologics
biopharmaceuticals
+13